Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118306 · ClinicalTrials.gov registry record
COPD Exacerbation Follow Up
A clinical trial, sponsored by Viz.ai.
- Recruiting
- Registry status
- 485
- Enrollment target
NCT07118306: Recruiting study, sponsored by Viz.ai.
NCT07118306 is a clinical trial that is actively recruiting participants, run by Viz.ai. The registered enrollment target is 485 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07118306 is actively recruiting participants, sponsored by Viz.ai.
- RECRUITING
- Registry status
- 485 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
Primary Outcome
Proportion of patients with a respiratory specialist follow-up visit within 30 days after discharge in the experimental cohort compared to the control cohort.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-12 |
What NCT07118306 shows while recruiting
NCT07118306 is an observational study that tracks outcomes without assigning an intervention. The registered 485 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07118306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07118306 about?
NCT07118306 is a clinical study titled "COPD Exacerbation Follow Up". The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
What is the current status of trial NCT07118306?
This trial is currently recruiting. The enrollment target is 485 participants. The study started on 2026-02-27. Estimated completion is 2027-12.
Who is sponsoring clinical trial NCT07118306?
This trial is sponsored by Viz.ai, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI